Abstract | BACKGROUND: METHODS: RESULTS: Of the 56 women, 24 (43%) were taking HT at entry, with median fasting triglycerides 1270 mg/dl in the HT group and 1087 mg/dl in the no-HT group. Seventeen women (30%) had a history of AP, nine of whom (53%) were/had been on HT at the development of AP. Significant positive correlates of triglycerides at entry in a stepwise regression model were hemoglobin A(1C) (partial r(2)=10.7%, p<0.05) and an interaction between estrogen use and familial hypertriglyceridemia (partial r(2)=15%, p=0.017). After 2-4 weeks on therapy, median triglycerides in the previous-HT group fell from 1270 to 284 mg/dl (p<0.0001) and in the no-HT group from 1087 to 326 mg/dl (p<0.0001). CONCLUSIONS:
|
Authors | Naila M Goldenberg, Ping Wang, Charles J Glueck |
Journal | Clinica chimica acta; international journal of clinical chemistry
(Clin Chim Acta)
Vol. 332
Issue 1-2
Pg. 11-9
(Jun 2003)
ISSN: 0009-8981 [Print] Netherlands |
PMID | 12763274
(Publication Type: Comment, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Fatty Acids, Omega-3
- Hypolipidemic Agents
- Selective Estrogen Receptor Modulators
- Triglycerides
- Gemfibrozil
|
Topics |
- Adult
- Aged
- Diabetes Mellitus, Type 2
(blood, complications)
- Drug Interactions
- Estrogen Replacement Therapy
(adverse effects)
- Fatty Acids, Omega-3
(therapeutic use)
- Female
- Gemfibrozil
(therapeutic use)
- Hormone Replacement Therapy
(adverse effects)
- Humans
- Hyperlipoproteinemia Type IV
(blood, complications)
- Hypertriglyceridemia
(complications, etiology, prevention & control)
- Hypolipidemic Agents
(therapeutic use)
- Middle Aged
- Pancreatitis
(complications, etiology, prevention & control)
- Retrospective Studies
- Selective Estrogen Receptor Modulators
(therapeutic use)
- Statistics as Topic
- Triglycerides
(blood)
|